MBX-2982: Phase I data

A placebo-controlled, multiple ascending-dose Phase I trial in about 45 pre-diabetics showed that 5 consecutive once-daily doses of 25, 100, 300 or 600 mg MBX-2982 significantly reduced glucose excurs...